Prokineticin 2 (PROK2) is an important factor for angiogenesis in colorectal cancer

Hidetaka Kurebayashi; Takanori Goi; Michiaki Shimada; Noriyuki Tagai; Takayuki Naruse; Toshiyuki Nakazawa; Youhei Kimura; Yasuo Hirono; Akio Yamaguchi

doi:10.18632/oncotarget.4385

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Prokineticin 2 (PROK2) is an important factor for angiogenesis in colorectal cancer

Hidetaka Kurebayashi　, Takanori Goi _, Michiaki Shimada, Noriyuki Tagai, Takayuki Naruse, Toshiyuki Nakazawa, Youhei Kimura, Yasuo Hirono and Akio Yamaguchi

PDF | HTML | How to cite

Oncotarget. 2015; 6:26242-26251. https://doi.org/10.18632/oncotarget.4385

Metrics: PDF 3700 views | HTML 2490 views | ?

Abstract

Hidetaka Kurebayashi1, Takanori Goi1, Michiaki Shimada1, Noriyuki Tagai1, Takayuki Naruse1, Toshiyuki Nakazawa1, Youhei Kimura1, Yasuo Hirono1, Akio Yamaguchi1

1Department of Surgery, University of Fukui, Fukui 9101193, Japan

Correspondence to:

Takanori GOI, e-mail: [email protected]

Keywords: colorectal cancer, prokineticin 2, angiogenesis

Received: April 01, 2015 Accepted: June 19, 2015 Published: June 30, 2015

ABSTRACT

The Prokineticin 2 (PROK2) is correlated with indispensable in maintaining the homeostasis of healthy human tissues. Herein, we examined the role of PROK2 in human colorectal cancer.

After total RNA extraction from 6 colorectal cancer cell lines, we examined the expression of PROK2 mRNA. For investigating angiogenesis and tumor growth in mice, the PROK2 gene was transfected into colorectal cancer cell lines having low PROK2 mRNA expression. In addition, small interfering RNA (siRNA) was transfected into colorectal cancer cell lines having high PROK2 mRNA expression for investigation of angiogenesis and tumor growth in mice.

From 6 colorectal cancer cell lines studied, PROK2 mRNA expression was increased in 3 cell lines. When the PROK2 gene was transfected into the colorectal cancer cell line with low PROK2 mRNA expression, angiogenesis and tumor growth in mice increased significantly compared to the cell line with the control vector.

When PROK2 siRNA was transfected into colorectal cancer cell lines with high PROK2 mRNA expression, angiogenesis and tumor growth in mice were suppressed significantly compared to the cell line with siRNA (control).

This is the first report of the association of PROK2 as an angiogenic growth factor in colorectal cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4385

Publication Alerts

Research Papers:

Prokineticin 2 (PROK2) is an important factor for angiogenesis in colorectal cancer

Abstract